Tagged with CTI

Austria Eva Bano, CEO of BANO, an exciting west Austrian company, discusses the company’s modern revamp and expansion from natural therapies to pharmaceutical products. She also explains the importance of a strong online presence, the opening of a new production plant and the distribution services they offer for potential partners within…

Ukraine Roman Gladkyi, general manager of Ferring Ukraine, describes the current opportunities and areas for improvement he identifies within Ukraine’s pharmaceutical market and the country’s evolving heath system, with a special focus on Ferring’s key areas of expertise such as reproductive health and obstetric products. You have been heading Ferring Ukraine…

Switzerland With more than 20 years of experience working with the Swiss pharmaceutical sector, general manager Roland Laudenbacher explains that Honeywell Building Solutions has developed a true specialization in projects for pharma clients, including their own in house GMP validation services. To begin, could you please introduce Honeywell Business Solutions, and…

Ireland Much like the Irish sport of hurling, conducting R&D in Ireland is something often overlooked – unfairly, as proponents would say. Ireland has always faced a number of intrinsic hurdles in this space, not least the small patient population and more recently, the economic crisis, which forced the Irish healthcare…

Switzerland With over 50 years of history in Switzerland, Zambon operates in Canton Ticino one of Zambon’s two major global production centers. Swiss Market  Manager Giampiero Roncoroni discusses the unique features of the Swiss market, and how a particular focus on the OTC/OTX market has been a key factor of success…

Mexico Mario Sturion, the recently appointed general manager of Janssen Mexico, assesses the specific challenges and opportunities of the Mexican health system and explains how a customized market access approach has been critical to Janssen’s success in a country noteworthy for the complexity of its public health system. You took over…

Ireland Darren Cunningham tells us the story behind Inflection Biosciences (and its name), the rationale of focusing on small molecule cancer treatments, his thoughts on the Irish biotech start-up scene, and his hopes for the company’s future development. Can you first provide an introduction to Inflection Biosciences to our international audience? “The Irish…

Switzerland Walter Steinlin describes the Federal Commission of Technology and Innovation as a catalyst for turning research into innovation. Based in Bern, Switzerland, the commission funds research institutes in corporate projects, and provides mentorship and coaching support for start-ups. Could you give our international audience an overview of the Federal Commission…

Pharma The following map shows the importance of the pharmaceutical industry to the highly regionalised Italian industry. Lombardy in the North of Italy employs 27,000 people in pharmaceuticals and is ranked number one for pharma and biotech firms. Click here to read more articles and interviews from Italy, and to download…

Health For Cristóbal Thompson, Executive Director of AMIIF, health is a formidable measure of productivity and competitiveness that Mexico can no longer overlook if it is to sustain robust economic growth. He details how the organization has been able to assemble a growing number of powerful allies behind this cause, and points…

Pharma Following regulatory changes, CSL Behring is now able to offer plasma fractionation and purification services to Italy’s public healthcare sector for the first time. General manager Oliver Schmitt discusses the added value and savings CSL Behring can offer in this service segment and the benefits its newest generation of innovative…

Pharma PwC Italy’s Rodrigue G. Schübelin talks maintaining Italy’s impressive growth in pharma production, R&D incentives, public-private collaboration, and PwC’s role within the Italian healthcare ecosystem. Italy’s pharmaceutical production increased by 38 percent from 2009 to 2014; what steps does the industry need to take to keep performing at this level?…